{
    "paper_id": "611aeb0d4282b5f081c38f107d4e96965ec30003",
    "metadata": {
        "title": "A",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Peritoneal dialysis (PD) (Continued) prevalence of use, 187-188 survival, 191-192, 191t visually-impaired patients, 190 ",
            "cite_spans": [
                {
                    "start": 56,
                    "end": 119,
                    "text": "187-188 survival, 191-192, 191t visually-impaired patients, 190",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Salicylate poisoning",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "835--836",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Severe acute respiratory syndrome (SARS). Schwartz formula",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Sars",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "See",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Sclerosing encapsulating peritonitis (SEP)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "578",
            "issn": "",
            "pages": "594--596",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Seldinger technique, peritoneal dialysis catheter placement",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "523--524",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Drug dosing. See Pharmacology. DSS. See Dialysis disequilibrium syndrome (DSS). DWGF. See Death with graft function (DWGF). See Focal segmental glomerulosclerosis (FSGS). FSH. See Follicle-stimulating hormone (FSH). Hernia, peritoneal dialysis patients, 598-600 HGF. See Hepatocyte growth factor (HGF). High flux membranes, 365 Hippuric acid, uremic toxicity, 96 Hirudin, 330 HIT. See Heparin-induced thrombocytopenia (HIT). HIV. See Human immunodeficiency virus (HIV). HIVAN. See Human immunodeficiency virus-associated nephropathy (HIVAN). Hollow fiber dialyzer, 316 Home-based dialysis, 281 Homocysteine cardiovascular disease risks, 164-165, 164t kidney transplant recipient hyperhomocysteinemia, 700 uremic toxicity, 96 HOPE. See Heart Outcomes Prevention Evaluation (HOPE). Horseshoe kidney, 642, 642f HOT. See Hypertension Optimal Treatment trial (HOT). HTLV-I. See Human T-lymphotropic virus I (HTLV-I). David, 632, 633f HUS. See Hemolytic uremic syndrome (HUS). Hyaluronan, peritoneal membrane effluent soluble marker, 502 Hyaluronic acid, uremic toxicity, 97 Hydraulic pressure, 308 Hydrothorax, peritoneal dialysis patients, 596-598 Hydroxyhippuric acid, uremic toxicity, 98 See Irbesartan Diabetic Nephropathy Trial (IDNT). IDPN. See Intradialytic parenteral nutrition (IDPN). IgA nephropathy. See Immunoglobulin A (IgA) nephropathy IGF-I. See Insulin-like growth factor-1 (IGF-I). IHD. See Ischemic heart disease (IHD). See Epidemiology, chronic kidney disease. Indoles, uremic toxicity, 97 Indoxyl sulfate, uremic toxicity, 97 Induction therapy. See Immunosuppression therapy. Infection. See also Microbial contamination; Peritonitis; specific pathogens. Janus kinase (JNK), 779 JC virus, m renal transplant recipient infection, 693 JNK. See Janus kinase (JNK). K 0 A. See Hemodialyzers. KDQI. See Kidney Disease Outcomes Quality Initiative (KDQI). KEEP. See Kidney Early Evaluation Program (KEEP).",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "waiting time on dialysis effects on outcomes, 284 xenotransplantation. See Xenotransplantation. KIM-1, 771, 779 Kolff, Willem, 307 Kt/V. See Hemodialysis. K Uf . See Ultrafiltration coefficient (K Uf ). Lactic acid, serum elevation in peritoneal dialysis patients, 593 Lanthanum carbonate, phosphate binding, 146 Law of conservation of mass, 407 LBP. See Lipopolysaccharide-binding protein (LBP). LCDD. See Light chain deposition disease (LCDD). LDL. See Low-density lipoprotein (LDL). Magnesium. See Peritoneal dialysis solutions.",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Personal dialysis capacity test (PDC), 500t, 501 PET. See Peritoneal equilibration test (PET). Phenols, uremic toxicity, 100-101 Phenylacetylglutamine, uremic toxicity, 100 Phosphorous control in secondary hyperparathyroidism dietary restriction, 144-145 phosphate binders, 145-147 nutrition, 223, 226 pediatric chronic kidney disease patient intake, 270 uremic toxicity, 101 Pimagedine, advanced glycation end product inhibition, 44 PKC. See Protein kinase C (PKC). Platelet-activating factor (PAF), 100 PLMD. See Periodic limb movement disorder (PLMD). Sevelamer, phosphate binding, 146 Severe acute respiratory syndrome (SARS), kidney transplantation, 689 Sex differences glomerular filtration rate, 4 hemodialysis adequacy, 419 renal replacement therapy incidence for end-stage renal disease, 6 SFGC. See Sodium Ferric Gluconate Complex (SFGC). SGA. See Subjective global assessment (SGA). SHEP. See Systolic Hypertension in the Elderly Program (SHEP). See Systemic lupus erythematosus (SLE). Sleep disorders. See also Periodic limb movement disorder (PLMD); Restless legs syndrome (RLS). assessment, 247 cardiovascular consequences, 248 insomnia and circadian rhythm abnormalities, 252 kidney transplant patients, 249-251 management challenges, 252, 254-255, 255t mechanisms in renal disease, 249-250 metabolic and infectious consequences, 249 prevalence in renal disease, 248-249 quality of life consequences, 249 Stem cells, renal replacement therapy prospects, 753-754 Stenotrophomona, 575 Streaming effect, 318 Streptococcus viridans, peritonitis management, 580 Stress testing, 166 Stroke, kidney transplant recipients, 702 Strongyloides stercoralis, renal transplant recipient infection, 681 Strontium, 102 Subjective global assessment (SGA), 219 Sudden cardiac death, 169, 456-457 Supplemented very low-protein diet (SVLPD), 221 SVLPD. See Supplemented very low-protein diet (SVLPD). Swan-neck catheters, 520-521 Systemic lupus erythematosus (SLE). See Lupus nephritis. Systemic sclerosis, kidney transplant recipients, 715 Systolic Hypertension in the Elderly Program (SHEP), 40 TAC. See Time-averaged concentration (TAC). toxicity and graft dysfunction, 670-671 TAC urea , 406-407 Tartrate-resistant acid phosphatase, 141 Tenckhoff catheter, 518-519 Tenckhoff trocar, peritoneal dialysis catheter placement, 524-525 TGF-\u03b2. See Transforming growth factor-\u03b2 (TGF-\u03b2). Theophylline poisoning, 838 Thrombocytopenia, hemodialysis complication, 460 Thrombotic microangiopathy (TMA) graft dysfunction, 671-672 histology, 672, 672f Thrombotic thrombocytopenic purpura (TTP), kidney transplant recipients de novo disease, 715 recurrent disease, 714-715 Thymoglobulin, induction therapy for immunosuppression, 647, 650t Thyroid hormone, uremic syndrome derangements, 89-90 Ticlopidine, autogenous arteriovenous fistula patency improvement, 346 Time-averaged concentration (TAC), 406-407 Tissue engineering, renal replacement therapy prospects, 754 TLR-4. See Toll-like receptor-4 (TLR-4). TMA. See Thrombotic microangiopathy. TNF-\u03b1. See Tumor necrosis factor-\u03b1 (TNF-\u03b1). Tolerance, immune system, 619-620, 620t Toll-like receptor-4 (TLR-4), single nucleotide polymorphisms, 236 Trandolapril, 62 Transferrin, nutritional assessment, 218 Transferrin saturation (TSAT), 127 Transforming growth factor-\u03b2 (TGF-\u03b2) Transplant immunology (Continued) T-cell activation, 615-618 memory T-cells, 619 tolerance mechanisms, 619-620, 620t TRESAM study, 701 Trihalomethanes, uremic toxicity, 102 Trimethylamine, 98 Troponin I, 166 TSAT. See Transferrin saturation (TSAT). TTP. See Thrombotic thrombocytopenic purpura (TTP). Tuberculosis, kidney transplantation contraindication, 627 Tubular cell injury, acute renal failure lethal injury and resistance, 778-779 proximal tubular cell injury, 778 sublethal injury, 778 Tubulointerstitial kidney disease, epidemiology, 15-16 Tumor necrosis factor-\u03b1 (TNF-\u03b1) overview, 177-178 costs, 176 daily hemodialysis, 472-473 diabetic access syndrome, 176-177 geographic variation in type, 341 historical perspective, 341 infection, 437-438 recirculation, 323 subcutaneous ports, 343 survival based on access type, 341-342, 342f Vascular endothelial growth factor (VEGF), peritoneal membrane effluent VCUG. See Voiding cystourethrogram (VCUG). VEGF. See Vascular endothelial growth factor (VEGF). Venous air trap, 329 Ventricular arrhythmias, 169, 456-457 Vision loss. See also Diabetic retinopathy. hemodialysis complication, 465 Vitamin D analogs for renal osteodystrophy management, 147-148, 270-271 bone homeostasis role, 138-139 metabolism, 138-139, 139f pediatric chronic kidney disease management, 270-271 Vitamins nutrition, 223-224, 224t pediatric chronic kidney disease nutrition, 267-268 Voiding cystourethrogram (VCUG), 634 Volume of dialyzed compartment, 315 Volume of distribution, 828 Volume of urea distribution, 322 Voronoy, Y. Y., 632, 633f Wegener's granulomatosis, recurrence following kidney transplantation, 628 West Nile virus (WNV), kidney transplantation, 689 Whole body clearance, 319 WNV. See West Nile virus (WNV). Zoledronic acid, 150",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}